ofev
Boehringer’s TKI inhibitor Ofev gets FDA approval for chronic fibrosing interstitial lung diseases with a progressive phenotype
March 10, 2020Manufacturing and Production, Sales and Marketing Boehringer, FDA, ofev, pharma
The FDA has green-lit Boehringer Ingelheim’s multi-targeted tyrosine kinase inhibitor Ofev (nintedanib) in the treatment of chronic fibrosing interstitial lung …
Boehringer’s Ofev scores first-of-its-kind FDA approval in rare lung disease
September 10, 2019Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, FDA, US, lungs, ofev, pharma, rare disease
Boehringer Ingelheim’s Ofev (nintedanib) capsules have now secured marketing authorisation in the US, it has emerged, for the treatment of …
Boehringer launches IPF initiatives
February 29, 2016Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev
Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …
Boehringer’s OFEV slows IPF disease progression by half in trials
February 26, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, IPF, ofev
Boehringer Ingelheim has revealed pooled analysis data from three trials, showing that its drug OFEV significantly reduces the risk of …
Boehringer widens IPF drug’s reach
May 18, 2015Sales and Marketing Boehringer, Esbriet, ats, brett wells, nintedanib, ofev
Boehringer Ingelheim has highlighted new data for its idiopathic pulmonary fibrosis (IPF) treatment Ofev in a Phase II study on …
Boehringer assures future growth following sales drop
April 23, 2015Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results
Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …
Boehringer eyes Ofev success in IPF and beyond
March 16, 2015Sales and Marketing Boehringer, Esbriet, Roche, ingelheim, inpulsis, ipd, ofev
Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …
Boehringer gains EU approval for Ofev
January 19, 2015Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev
The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …
Boehringer’s lung cancer drug Vargatef sees EU approval
November 28, 2014Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef
Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …
CHMP nods several drugs through
November 24, 2014Sales and Marketing Boehringer, CHMP, EMA, Esbriet, FDA, Sanofi, nintedanib, ofev
Ten new medicines have been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP), among …
Growing IPF drugs market evident at ERS Congress
November 3, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ERS, Esbriet, IPF, elf, european respiratory society, ofev
Arriving in Germany for this year’s European Respiratory Society (ERS) International Congress 2014, what awaited Pharmafile at the Ausgang was …
Boehringer seeks more indications for IPF drug
October 22, 2014Research and Development, Sales and Marketing Boehringer, IPF, NSCLC, colectoral, crc, nintedanib, ofev
Boehringer Ingelheim’s nintedanib has entered Phase III studies for the treatment of colorectal cancer (CRC), which could add to the …
Boehringer and Roche IPF drugs win FDA approval
October 16, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev
The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …
